Literature DB >> 15897888

Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway.

Jinping Li1, Enfeng Wang, Francesca Rinaldo, Kaustubh Datta.   

Abstract

Androgen ablation therapy is eventually followed by a more metastatic and androgen-refractory stage of prostate cancer. The detailed molecular mechanism of this gradual transition is not clearly understood. Recent reports correlate the high abundance of vascular endothelial growth factor-C (VEGF-C) to the lymph node metastasis seen in human prostate cancer (Tsurusaki et al., 1999). In this study, we report that androgen ablation in LNCaP cells augment the transcriptional upregulation of VEGF-C and the downregulation of the IGF-IR pathway, due to androgen withdrawal, is a potential mechanism for this observed VEGF-C transcription. Forkhead transcription factor FOXO-1, activated by SIRT-1, was identified as the downstream molecule within this pathway. Furthermore, the VEGF-C-induced increase of Bag-IL expression in LNCaP cells suggests that VEGF-C plays a role in the androgen-independent reactivation of the androgen receptor, resulting in androgen-refractory prostate cancer growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897888     DOI: 10.1038/sj.onc.1208693

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1.

Authors:  Michael H Muders; Heyu Zhang; Enfeng Wang; Donald J Tindall; Kaustubh Datta
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

Review 2.  FOXOs in cancer immunity: Knowns and unknowns.

Authors:  Youcai Deng; Fangjie Wang; Tiffany Hughes; Jianhua Yu
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

Review 3.  Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.

Authors:  Jennifer Wu; Evan Yu
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 4.  Mechanism of lymph node metastasis in prostate cancer.

Authors:  Kaustubh Datta; Michael Muders; Heyu Zhang; Donald J Tindall
Journal:  Future Oncol       Date:  2010-05       Impact factor: 3.404

5.  Quantitative imaging of lymphatic function with liposomal indocyanine green.

Authors:  Steven T Proulx; Paola Luciani; Stefanie Derzsi; Matthias Rinderknecht; Viviane Mumprecht; Jean-Christophe Leroux; Michael Detmar
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

6.  Evaluation of benzoic acid derivatives as sirtuin inhibitors.

Authors:  Yi-Pei Chen; Chad C Catbagan; Jeannette T Bowler; Trevor Gokey; Natalie D M Goodwin; Anton B Guliaev; Weiming Wu; Taro Amagata
Journal:  Bioorg Med Chem Lett       Date:  2013-11-12       Impact factor: 2.823

7.  Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer.

Authors:  Heyu Zhang; Michael H Muders; Jinping Li; Francesca Rinaldo; Donald J Tindall; Kaustubh Datta
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 8.  Sirtuins in mammals: insights into their biological function.

Authors:  Shaday Michan; David Sinclair
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

9.  Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

Authors:  Arnab Chakravarti; Michelle DeSilvio; Min Zhang; David Grignon; Seth Rosenthal; Sucha O Asbell; Gerald Hanks; Howard M Sandler; Li-Yan Khor; Alan Pollack; William Shipley
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

10.  Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site.

Authors:  Kurtis Eisermann; Carly J Broderick; Anton Bazarov; Mustafa M Moazam; Gail C Fraizer
Journal:  Mol Cancer       Date:  2013-02-01       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.